UTStarcom Holdings Corp. (NASDAQ:UTSI), a global telecommunications infrastructure provider, announced a significant project win in India with Bharat Sanchar Nigam Limited (“BSNL”), a large public sector company that provides a comprehensive range of telecom services in India. BSNL is the Company’s major strategic customer in the region.

BSNL is upgrading its nationwide network that will offer Next generation voice and data services to its large customer base. UTStarcom was contracted to help build out the Class 5 Next Generation Network (“NGN”) infrastructure within the new network. NGN refers to packet-based networks, typically running Internet Protocol, that provide data, voice and media services by making use of multiple transport technologies.

UTStarcom Holdings Corp. (NASDAQ:UTSI)‘s stock on Friday traded at beginning with a price of $5.65 and when day-trade ended the stock finally slumped -10.87% to reach at $5.25. Analyst’s mean target price for UTSI is $5.00 while analysts mean recommendation is 2.00. Stock value has moved between $1.72 – 6.48 in last one year.

Analyst’s ratings determines the future of any company. Stock has got OUTPERFORM rating from 0 analyst(s) whereas last month 0 analyst(s) have given outperform rating. SELL rating has been given by 0 analyst(s) and 1 analyst(s) given BUY rating to the stock. Company fiscal year is ending in December and analysts’ consensus recommendation is Buy for UTSI.

UTStarcom Holdings Corp. (NASDAQ:UTSI) yearly performance is 191.67% and net profit margin is 1.00%. Annual EPS Growth of past 5 years is -50.20%. The current share price indicates that stock is -19.35% away from its one year high and is moving 205.23% ahead of its 52-week low.

On 09 March 2018, CRISPR Therapeutics AG (NASDAQ:CRSP) stock price started the day at $55.69 and moved between $55.65 – 61.24 to finally close at $56.72. CRSP’s distance from 20 day simple moving average is 28.51% and distance from 50-Day simple moving average is 55.53%. In last 4 months performance of CRSP was 206.10% while its price to sale ratio is 220.18 and price to book ratio is 12.72.

Analysts expect CRISPR Therapeutics AG (NASDAQ:CRSP) to report -1.56 EPS and has got OUTPERFORM rating from 5 of Thomson Reuters analysts and 0 analyst(s) given UNDERPERFORM rating. Analyst’s mean target price for CRSP is $32.17 while analysts mean recommendation is 2.10.

Tahoe Resources Inc. (NYSE:TAHO)‘s stock on Friday traded at beginning with a price of $4.53 and when day-trade ended the stock finally slumped -0.85% to reach at $4.68. Analyst’s mean target price for TAHO is $6.69 while analysts mean recommendation is 2.00. Stock value has moved between $3.77 – 9.75 in last one year.

Stock has got OUTPERFORM rating from 2 analyst(s) whereas last month 2 analyst(s) have given outperform rating. SELL rating has been given by 0 analyst(s) and 2 analyst(s) given BUY rating to the stock. Company fiscal year is ending in December and analysts’ consensus recommendation is Outperform for TAHO and estimated EPS for next quarter is 0.00.

Tahoe Resources Inc. (NYSE:TAHO) yearly performance is -41.13%. Annual EPS Growth of past 5 years is -4.81%. The current share price indicates that stock is -51.65% away from its one year high and is moving 24.47% ahead of its 52-week low.